CompletedNCT02398292
Official study titleMeals, Mindfulness & Moving Forward: A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youth Suffering From Psychosis
This study has finished and is no longer accepting participants.
In PortlandSchizophreniaInterventional studyAges 15–25
- Countries
- United States
- Sponsor
- Oregon Health and Science University
CompletedNCT00830739
This study has finished and is no longer accepting participants.
In BaltimoreAddictionObservational studyAges 18–55
- Countries
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
CompletedACTRN12617000354381
Official study titleAn investigation examining the efficacy and safety of a multi-nutrient intervention on symptoms of antenatal depression and anxiety in pregnant women who are symptomatic: A double blind, randomized, controlled trial
This study has finished and is no longer accepting participants.
In New ZealandDepression, AnxietyInterventional studyAges 16+
- Countries
- New Zealand
- Sponsor
- Professor Julia Rucklidge
No Longer AvailableNCT04438512
Official study titleAn Intermediate-size Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD
This study is no longer available.
Multiple locations, including RockvillePTSDMedication studyAges 18+
- Countries
- United States
- Sponsor
- Resilient Pharmaceuticals
CompletedNCT06291090
Official study titleIn Hospital Treatment of Opioid Use Disorder: Clinician Perspectives and Current Practices
This study has finished and is no longer accepting participants.
In AuroraAddictionBehavioural studyAges 18–99
- Countries
- United States
- Sponsor
- University of Colorado, Denver
CompletedNCT04714359
Official study titleA Multi-Site Open-Label Safety Extension Study of Manualized MDMA-Assisted Psychotherapy for the Treatment of Participants With Posttraumatic Stress Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Los AngelesPTSDMedication studyAges 18+
- Countries
- United States, Canada, Israel
- Sponsor
- Resilient Pharmaceuticals
CompletedNCT03537014
Official study titleA Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including North HollywoodPTSDMedication studyAges 18+
- Countries
- United States, Canada, Israel
- Sponsor
- Resilient Pharmaceuticals
CompletedNCT04077437
Official study titleA Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder of Moderate or Greater Severity
This study has finished and is no longer accepting participants.
Multiple locations, including Los AngelesPTSDMedication studyAges 18+
- Countries
- United States, Israel
- Sponsor
- Resilient Pharmaceuticals
WithdrawnNCT04454684
Official study titleAn Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating Disorders
This study was withdrawn before enrollment.
Location not clearly listedEating disordersMedication studyAges 21–65
- Countries
- Sponsor
- Resilient Pharmaceuticals
CompletedNCT00013000
This study has finished and is no longer accepting participants.
Multiple locations, including Washington D.C.SchizophreniaBehavioural studyAges 18–65
- Countries
- United States
- Sponsor
- US Department of Veterans Affairs
CompletedNCT00606229
What is this study about?This study evaluated the safety and effectiveness of Aripiprazole for people with bipolarity.
This study has finished and is no longer accepting participants.
Multiple locations, including Chugoku RegionBipolarityMedication studyAges 18–65
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
CompletedNCT02220712
What is this study about?This study evaluated the safety of OPC-14597 IMD for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Chugoku RegionSchizophreniaMedication studyAges 18–64
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)